Executive Summary

Sales for Rheumatoid Arthritis in the US

The Rheumatoid Arthritis (RA) market in the US is expected to grow at a Compound Annual Growth Rate (CAGR) of 2.0% during the forecast period, from 2013 sales of $10.4 billion to sales of $12.6 billion in 2023.

The major drivers for the growth of RA market in the US during the forecast period are:

- Launch of novel drugs, including oral JAK inhibitors and novel biologics for RA
- Aging population and increasing prevalent cases of RA
- Expanded access to medical care as a result of healthcare reform
- Establishment of regulatory guidelines for the approval of biosimilars

The major barriers to the growth of RA market in the US during the forecast period are:

- High out-of-pocket cost for biologics
- US Healthcare reform puts greater emphasis on the affordability of healthcare.

The figure below shows the sales for RA in the US by drug class during the forecast period.
Executive Summary

What Do Physicians Think?

The RA market is very competitive, and the new entrants are expected to be met with some resistance and experience slow uptake, as the market is currently dominated by the anti-TNFs, and rheumatologists feel comfortable with the long-term safety and efficacy of this class of drugs.

“We at least have a reasonably good handle on what the long-term or relatively long-term safety profile of [the] anti-TNFs is. They’re not perfect, but at least we know what the issues are, and there are concerns, I think, with the [the] long-term safety profiles of some of the new agents that have come through. And so, given that we rheumatologists feel more comfortable with the anti-TNFs…, we know what to look out for. Then, for any new players…, it can be difficult to compete because the concern is always, well, maybe the new drug might have long-term side effects, and so we better use the ones that we’ve got more — [that] we’re more familiar with.”

[EU] KOL

“Unless we can upfront identify a group in whom it’s [a pipeline agent] going to be effective…, [or] unless it’s marketed at a significantly lower cost than its competitors, what will happen is that the [new] drug will be used fourth or fifth line, etcetera. Because if it costs the same as a currently available biologic, the currently available biologics have got a stronger history, [a] longer history of maybe safety and efficacy data, [so] why would you choose to use the new one unless you’d actually tried and failed [with] the old ones? The problem with that, of course, for the new ones, is that they end up being tried on often the most difficult rheumatoid [arthritis] patients, and so, often they don’t work.”

[EU] KOL

One of the greatest challenges with the introduction of new biologics in the RA market will be to target these drugs to the right patients. Many rheumatologists believe that the future of RA is in individualized medicine, where biomarkers determine the best course of action for each patient.
“I think the patients find the whole process [of finding an effective therapy to be] very difficult. They often lose faith in our approach to treat their disease well. It may have an impact on their adherence to medication in the future. We kind of keep dropping and changing between one thing and another thing. How do they know that the fifth thing is going to work when the first four haven’t? Actually, adherence to drugs is a big issue in people with long-term conditions [such as RA], and the fact that it can take us a long time to find something that works, I think, is a big issue in the context of that for the patients as well.”

[UK] KOL

“I think it will be very difficult for rheumatologists to manage this huge number of different drugs that are available without us having some kind of strategy for establishing which groups of patients each particular drug would be most effective in, and so that kind of takes us down to [the] personalized medicine route, and I think that’s what companies need to be looking at as they’re developing these new agents….We need to work out who to treat with what — who to treat with what drug, based on identifying biomarkers that predict [the patient’s] response, which could be ones that you measure in the blood or [the] ones that you measure from the joint, but I think that will have to be the direction of travel.”

[EU] KOL

One of the greatest unmet needs in RA is the affordability of drugs, as the biologics cost upwards of $30,000 per year in the US. Biosimilars are expected to launch over the forecast period from 2013–2023 in all 10 markets covered in this report, changing the market dynamics and offering a less expensive alternative to the branded biologics.

“If a biosimilar is only half as expensive [as the originator brand] — which it’s probably not, [as that’s] probably overly optimistic — it’s still way out of the reach of most patients if they have [health insurance] coverage problems. Yes, it will help the overall system, but [it will] probably not help the individual patient very much. [I would prescribe biosimilars when they are available] sure, absolutely….You would potentially replace the innovative product with a biosimilar whenever you have that option. The only reason you do that, obviously, is cost. In most cases, it’s not going to be my decision; it’s going to be the decision of whoever is paying for it….It will be helpful, but it’s not going to be a big game-changer….Two thirds of [what is already] a heck of a lot of money is still almost a heck of a lot of money, and most people don’t have that.”

[US] KOL
Table of Contents

1 Table of Contents .......................................................................................................................... 5
  1.1 List of Tables ............................................................................................................................ 10
  1.2 List of Figures .......................................................................................................................... 14
2 Introduction .................................................................................................................................. 15
  2.1 Catalyst ..................................................................................................................................... 15
  2.2 Related Reports ........................................................................................................................ 16
  2.3 Upcoming Related Reports ....................................................................................................... 19
3 Disease Overview ......................................................................................................................... 20
  3.1 Etiology and Pathophysiology ................................................................................................. 20
    3.1.1 Etiology ............................................................................................................................. 20
    3.1.2 Pathophysiology ............................................................................................................... 20
  3.2 Symptoms .................................................................................................................................. 25
  3.3 Prognosis .................................................................................................................................... 25
  3.4 Quality of Life ........................................................................................................................... 26
4 Disease Management .................................................................................................................... 27
  4.1 Diagnosis and Treatment Overview ....................................................................................... 27
    4.1.1 Diagnosis ............................................................................................................................. 27
    4.1.2 Treatment Guidelines ......................................................................................................... 29
    4.1.3 Leading Prescribed Drugs for the Treatment of RA ............................................................ 37
    4.1.4 Clinical Practice ................................................................................................................... 38
  4.2 US ............................................................................................................................................ 42
# Table of Contents

## 5 Competitive Assessment

5.1 Overview ................................................................. 47
5.2 Product Profiles – Major Brands ................................ 48
  5.2.1 Enbrel (etanercept) ................................................. 48
  5.2.2 Humira (adalimumab) ............................................. 54
  5.2.3 Remicade (infliximab) ............................................ 57
  5.2.4 Simponi (golimumab) ............................................. 62
  5.2.5 Cimzia (certolizumab pegol) ................................... 66
  5.2.6 Orencia (abatacept) .............................................. 70
  5.2.7 Actemra/RoActemra (tocilizumab) ......................... 75
  5.2.8 Rituxan/MabThera (rituximab) ............................... 81
  5.2.9 Inflectra/Remsima (infliximab biosimilar) ............... 86
  5.2.10 Xeljanz (tofacitinib) ........................................... 89
  5.2.11 Methotrexate (Numerous Brands) ......................... 95
5.3 Biosimilars ................................................................ 98
  5.3.1 Introduction .......................................................... 98
  5.3.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases .......... 100
  5.3.3 Biosimilars in the Immunology Community ............... 101
  5.3.4 By the Numbers: Biosimilars in Development .......... 101
  5.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry .... 105
  5.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market ................. 106
5.4 Other Therapies ........................................................... 109

## 6 Unmet Need and Opportunity ........................................... 110
## Table of Contents

6.1 Overview .................................................................................................................. 110

6.2 Development of Cost-Effective Therapies ................................................................. 111
   6.2.1 Unmet Need ........................................................................................................ 111
   6.2.2 Gap Analysis ..................................................................................................... 112
   6.2.3 Opportunity ....................................................................................................... 112

6.3 Biomarkers to Predict Responsiveness to Therapy .................................................... 112
   6.3.1 Unmet Need ........................................................................................................ 112
   6.3.2 Gap Analysis ..................................................................................................... 114
   6.3.3 Opportunity ....................................................................................................... 115

6.4 Early Diagnosis of RA ............................................................................................... 115
   6.4.1 Unmet Need ........................................................................................................ 115
   6.4.2 Gap Analysis ..................................................................................................... 116
   6.4.3 Opportunity ....................................................................................................... 117

6.5 Personalized Treatment Approach ............................................................................ 118
   6.5.1 Unmet Need ........................................................................................................ 118
   6.5.2 Gap Analysis ..................................................................................................... 118
   6.5.3 Opportunity ....................................................................................................... 120

7 Pipeline Assessment ....................................................................................................... 122

7.1 Overview .................................................................................................................. 122

7.2 Promising Drugs in Clinical Development ............................................................... 122
   7.2.1 Sarilumab ........................................................................................................... 129
   7.2.2 Sirukumab ......................................................................................................... 136
   7.2.3 Clazakizumab ................................................................................................. 142
# Table of Contents

7.2.4 Cosentyx (secukinumab) ................................................................. 148
7.2.5 Tregalizumab ................................................................................. 153
7.2.6 Mavrilimumab ................................................................................. 158
7.2.7 Baricitinib ...................................................................................... 163
7.2.8 Peficitinib ...................................................................................... 171
7.2.9 Decernotinib .................................................................................. 176
7.2.10 Filgotinib ..................................................................................... 180
7.2.11 Masitinib ...................................................................................... 185
7.2.12 RAVAX .......................................................................................... 191
7.3 Other Drugs in Development .............................................................. 196

8 Market Outlook .................................................................................. 199
8.1 Drivers and Barriers – Global Issues .................................................... 199
  8.1.1 Driver: Launch of novel drugs, including oral JAK inhibitors and novel biologics for RA ................................................................. 199
  8.1.2 Driver: Earlier diagnosis and treatment .............................................. 199
  8.1.3 Driver: Market entry of biosimilars will bring a therapy option for those who cannot afford branded biologics ......................................................... 200
  8.1.4 Driver: Aging population and increasing prevalent cases of RA ................................................................. 200
  8.1.5 Barrier: Efforts to reduce costs in the treatment of RA.......................... 201
  8.1.6 Barrier: Lack of regulatory guidelines for biosimilars will delay their availability in some regions ................................................................. 201
  8.1.7 Barrier: Entry of biosimilars will create a less expensive treatment alternative .......... 201
8.2 United States ..................................................................................... 202
# Table of Contents

8.2.1 Forecast .................................................................................................................. 202
8.2.2 Key Events .............................................................................................................. 207
8.2.3 Drivers and Barriers – US ...................................................................................... 208

9 Appendix ....................................................................................................................... 211
9.1 Bibliography ............................................................................................................... 211
9.2 Abbreviations ............................................................................................................. 225
9.3 Methodology .............................................................................................................. 230
9.4 Forecasting Methodology .......................................................................................... 230
9.4.1 Diagnosed RA Patients ......................................................................................... 230
9.4.2 Percentage of Drug-Treated Patients .................................................................... 231
9.4.3 Drugs Included in Each Therapeutic Class ......................................................... 231
9.4.4 Launch and Patent Expiry Dates .......................................................................... 232
9.4.5 General Pricing Assumptions ............................................................................... 233
9.4.6 Individual Drug Assumptions .............................................................................. 234
9.4.7 Generic and Biosimilar Erosion ........................................................................... 243
9.4.8 Pricing of Pipeline Agents .................................................................................... 243
9.5 Primary Research – KOLs Interviewed for This Report ............................................ 245
9.6 Primary Research – Prescriber Survey ..................................................................... 247
9.7 About the Authors ..................................................................................................... 248
9.7.1 Analyst .................................................................................................................... 248
9.7.2 Reviewer ................................................................................................................ 248
9.7.3 Therapy Area Director .......................................................................................... 249
9.7.4 Global Head of Healthcare ................................................................................... 249
# Table of Contents

9.8 About GlobalData ........................................................................................................... 250
9.9 Disclaimer ..................................................................................................................... 250

## 1.1 List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1</td>
<td>Symptoms of RA</td>
<td>25</td>
</tr>
<tr>
<td>Table 2</td>
<td>1987 ACR Diagnostic Criteria for RA</td>
<td>28</td>
</tr>
<tr>
<td>Table 3</td>
<td>2010 ACR/EULAR Diagnostic Criteria for RA</td>
<td>29</td>
</tr>
<tr>
<td>Table 4</td>
<td>Treatment Guidelines for RA Used in the US</td>
<td>31</td>
</tr>
<tr>
<td>Table 5</td>
<td>ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity</td>
<td>33</td>
</tr>
<tr>
<td>Table 6</td>
<td>EULAR 2013 Criteria for RA Remission</td>
<td>34</td>
</tr>
<tr>
<td>Table 7</td>
<td>Most Prescribed Biologics for RA (After csDMARDs) in the US Markets, 2014</td>
<td>38</td>
</tr>
<tr>
<td>Table 8</td>
<td>RA Treatment Country Profile – US</td>
<td>46</td>
</tr>
<tr>
<td>Table 9</td>
<td>Leading Branded Treatments for RA 2014</td>
<td>48</td>
</tr>
<tr>
<td>Table 10</td>
<td>Product Profile – Enbrel</td>
<td>50</td>
</tr>
<tr>
<td>Table 11</td>
<td>10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers</td>
<td>51</td>
</tr>
<tr>
<td>Table 12</td>
<td>10-year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results</td>
<td>52</td>
</tr>
<tr>
<td>Table 13</td>
<td>Enbrel SWOT Analysis, 2014</td>
<td>53</td>
</tr>
<tr>
<td>Table 14</td>
<td>Product Profile – Humira</td>
<td>55</td>
</tr>
<tr>
<td>Table 15</td>
<td>Humira SWOT Analysis, 2014</td>
<td>57</td>
</tr>
<tr>
<td>Table 16</td>
<td>Product Profile – Remicade</td>
<td>59</td>
</tr>
<tr>
<td>Table 17</td>
<td>Remicade SWOT Analysis, 2014</td>
<td>62</td>
</tr>
<tr>
<td>Table 18</td>
<td>Product Profile – Simponi</td>
<td>64</td>
</tr>
<tr>
<td>Table 19</td>
<td>Simponi SWOT Analysis, 2014</td>
<td>66</td>
</tr>
</tbody>
</table>
# Table of Contents

Table 20: Product Profile – Cimzia ................................ ................................ ................................ .............. 68
Table 21: Cimzia SWOT Analysis, 2014 ........................................................................................................... 70
Table 22: Product Profile – Orencia ................................ ................................ ................................ ............. 72
Table 23: Orencia SWOT Analysis, 2014 ....................................................................................................... 75
Table 24: Product Profile – Actemra ............................................................................................................... 79
Table 25: Actemra SWOT Analysis, 2014 ..................................................................................................... 81
Table 26: Product Profile – Rituxan .............................................................................................................. 84
Table 27: Rituxan SWOT Analysis, 2014 ...................................................................................................... 85
Table 28: Product Profile – Inflectra/Remsima ............................................................................................ 87
Table 29: Inflectra/Remsima SWOT Analysis, 2014 .................................................................................... 88
Table 30: Product Profile – Xeljanz ............................................................................................................. 92
Table 31: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6 ............... 93
Table 32: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6 ......................... 93
Table 33: Xeljanz SWOT Analysis, 2014 .................................................................................................. 95
Table 34: Product Profile – MTX .................................................................................................................. 97
Table 35: MTX SWOT Analysis, 2014 ......................................................................................................... 98
Table 36: Biosimilars Pipeline for RA, 2013 ................................................................................................. 102
Table 37: Physician Uptake of Biosimilar Products for RA in the US, 2014 .................................................. 108
Table 38: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2014 ................................. 109
Table 39: Unmet Need and Opportunity in RA, 2014 .............................................................................. 111
Table 40: Comparison of Therapeutic Drug Classes in Development for RA, 2014 ............................... 129
Table 41: Product Profile – Sarilumab ......................................................................................................... 131
Table 42: MOBILITY Study Part, A, Results for Sarilumab at Week 12 ...................................................... 132
Table 43: MOBILITY Study, Part B, Results for Sarilumab at Week 52 ...................................................... 132
Table of Contents

Table 44: Sarilumab SWOT Analysis, 2014 ................................................................. 136
Table 45: Product Profile – Sirukumab ................................................................. 137
Table 46: Sirukumab SWOT Analysis, 2014 ......................................................... 141
Table 47: Product Profile – Clazakizumab ............................................................ 143
Table 48: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks .... 144
Table 49: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks .... 144
Table 50: Clazakizumab SWOT Analysis, 2014 .................................................... 147
Table 51: Product Profile – Cosentyx ................................................................. 150
Table 52: Cosentyx SWOT Analysis, 2014 .......................................................... 153
Table 53: Product Profile – Tregalizumab ............................................................. 155
Table 54: Tregalizumab SWOT Analysis, 2014 .................................................... 158
Table 55: Product Profile – Mavrilimumab ........................................................... 159
Table 56: Mavrilimumab SWOT Analysis, 2014 ................................................... 163
Table 57: Product Profile – Baricitinib ................................................................. 165
Table 58: Baricitinib Phase IIb Trial, Part A: ACR Responses at Week 12 .......... 166
Table 59: Baricitinib Phase IIb Trial, Part B: ACR Responses at Weeks 24 and 52 ... 166
Table 60: Baricitinib Phase IIb Trial, Part A: Safety at Week 12 ......................... 167
Table 61: Baricitinib Phase IIb Trial, Part A, Laboratory Values at Week 12 ....... 168
Table 62: Baricitinib SWOT Analysis, 2014 ......................................................... 171
Table 63: Product Profile – Peficitinib ................................................................. 172
Table 64: Peficitinib SWOT Analysis, 2014 .......................................................... 175
Table 65: Product Profile – Decernotinib ............................................................ 176
Table 66: Phase IIb Study of Decernotinib: ACR Responses at Week 24 ......... 177
Table 67: Decernotinib SWOT Analysis, 2014 .................................................... 180
Table of Contents

Table 68: Product Profile – Filgotinib.................................................................181
Table 69: Filgotinib SWOT Analysis, 2014 .................................................................185
Table 70: Product Profile – Masitinib.................................................................186
Table 71: ACR Response to Masitinib in RA (12 Weeks)...............................................187
Table 72: ACR Responses for Masitinib in the Phase IIa ITT Population (12–82 Weeks)..............................188
Table 73: Masitinib SWOT Analysis, 2014...............................................................191
Table 74: Product Profile – RAVAX.................................................................192
Table 75: RAVAX SWOT Analysis, 2014...............................................................195
Table 76: Drugs in Phase II of Development for RA, 2014 ...........................................197
Table 77: Global RA Market – Drivers and Barriers, 2013–2023 ....................................199
Table 78: Sales Forecasts ($m) for RA in the United States, 2013–2023.................................204
Table 79: Key Events Impacting Sales for RA in the US, 2013–2023.................................207
Table 80: RA Market in the US – Drivers and Barriers, 2013–2023.................................208
Table 81: Key Launch Dates of RA Products in the US ..................................................232
Table 82: Key Patent Expiries...................................................................................233
Table 83: High-Prescribing Physicians (non-KOLs) Surveyed in the US............................247
Table of Contents

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA ................................................................. 21
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs ......................................................... 24
Figure 3: Disease Management Flowchart for Early RA – ACR 2012 ......................................................... 34
Figure 4: Disease Management Flowchart for Established RA – ACR 2012 ............................................. 35
Figure 5: Flowchart for the Management of RA – EULAR 2013 ................................................................. 36
Figure 6: Biosimilar Prescribing Habits in RA Across the 10MM, 2014 ..................................................... 108
Figure 7: RA – Phase II–III Pipeline, 2014 ................................................................................................ 124
Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013–2023 ............................... 128
Figure 9: Clinical and Commercial Positioning of Sarilumab ................................................................. 135
Figure 10: Clinical and Commercial Positioning of Sirukumab ............................................................... 141
Figure 11: Clinical and Commercial Positioning of Clazakizumab .......................................................... 147
Figure 12: Clinical and Commercial Positioning of Cosentyx .................................................................. 152
Figure 13: Clinical and Commercial Positioning of Tregalizumab ......................................................... 157
Figure 14: Clinical and Commercial Positioning of Mavrilimumab ....................................................... 162
Figure 15: Clinical and Commercial Positioning of Baricitinib ............................................................... 170
Figure 16: Clinical and Commercial Positioning of Peficitinib .............................................................. 175
Figure 17: Clinical and Commercial Positioning of Decernotinib .......................................................... 179
Figure 18: Clinical and Commercial Positioning of Filgotinib ............................................................... 184
Figure 19: Clinical and Commercial Positioning of Masitinib ............................................................... 190
Figure 20: Clinical and Commercial Positioning of RAVAX ................................................................. 195
Figure 21: Sales for RA in the United States by Drug Class, 2013–2023 ............................................... 206
2 Introduction

2.1 Catalyst

The Rheumatoid Arthritis (RA) market will grow over the 2013–2023 forecast period, driven by a number of new product launches, such as:

- Novel biologics
- Anti-interleukin (IL)-6 biologics
- Small molecules, including janus kinase (JAK) inhibitors

Other factors that will drive market expansion are growth in the emerging markets of China, India, and Australia, where product launches extend product lifecycles. In addition, there will be an increase in the prevalence of RA across the 10 major markets (10MM) covered in this report.

The loss of patent protection for the anti-tumor necrosis factor (TNF) marketed brands will allow for the emergence of biosimilars, such as Celltrion’s Remsima (infliximab)/Hospira’s Inflectra (infliximab), which is a Remicade biosimilar. The patent expiries begin in 2015 and 2016, respectively, for the current market leaders:

- J&J’s Remicade
- AbbVie’s Humira

The catalysts and objectives for this report are to:

- Determine the impact that biosimilars will have on the RA market
- Assess the uptake of JAK inhibitors, including Pfizer’s Xeljanz (tofacitinib) and other pipeline agents
- Identify the unmet needs in the RA market
- Determine the remaining opportunities in the RA market
Introduction

2.2 Related Reports

Introduction

- GlobalData (2014). Rituxan/MabThera (rituximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC499DFR
- GlobalData (2014). Sarilumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC504DFR
Introduction

- GlobalData (2014). Denosumab (Prolia) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC510DFR
- GlobalData (2014). Decernotinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC513DFR
- GlobalData (2014). Filgotinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC514DFR
- GlobalData (2014). Masitinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC515DFR
2.3 Upcoming Related Reports

Appendix

9.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

9.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.